MoonLake Immunotherapeutics (MLTX) Projected to Post Earnings on Thursday

MoonLake Immunotherapeutics (NASDAQ:MLTX) is anticipated to issue its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.89) per share for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 7:00 AM ET.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.14). During the same period last year, the firm posted ($0.39) earnings per share. On average, analysts expect MoonLake Immunotherapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

MoonLake Immunotherapeutics Stock Down 2.1%

Shares of NASDAQ:MLTX opened at $9.61 on Thursday. The company has a market cap of $617.25 million, a price-to-earnings ratio of -3.46 and a beta of 1.10. MoonLake Immunotherapeutics has a 12 month low of $5.95 and a 12 month high of $62.75. The company has a current ratio of 16.65, a quick ratio of 16.65 and a debt-to-equity ratio of 0.21. The company has a 50-day moving average price of $34.23 and a 200 day moving average price of $41.64.

Insider Buying and Selling at MoonLake Immunotherapeutics

In related news, major shareholder Bihua Chen sold 5,827 shares of the stock in a transaction that occurred on Tuesday, September 30th. The shares were sold at an average price of $6.96, for a total transaction of $40,555.92. Following the completion of the transaction, the insider owned 1,994,173 shares of the company’s stock, valued at approximately $13,879,444.08. This trade represents a 0.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 12.02% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Several institutional investors have recently modified their holdings of the company. Vestal Point Capital LP lifted its position in MoonLake Immunotherapeutics by 175.0% in the second quarter. Vestal Point Capital LP now owns 550,000 shares of the company’s stock valued at $25,960,000 after acquiring an additional 350,000 shares during the last quarter. Hudson Bay Capital Management LP lifted its position in MoonLake Immunotherapeutics by 31.3% in the second quarter. Hudson Bay Capital Management LP now owns 105,000 shares of the company’s stock valued at $4,956,000 after acquiring an additional 25,000 shares during the last quarter. Balyasny Asset Management L.P. boosted its stake in shares of MoonLake Immunotherapeutics by 436.8% during the second quarter. Balyasny Asset Management L.P. now owns 423,170 shares of the company’s stock worth $19,974,000 after buying an additional 344,335 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of MoonLake Immunotherapeutics by 13.1% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,752 shares of the company’s stock worth $743,000 after buying an additional 1,819 shares during the period. Finally, Alliancebernstein L.P. boosted its stake in shares of MoonLake Immunotherapeutics by 17.8% during the second quarter. Alliancebernstein L.P. now owns 1,138,022 shares of the company’s stock worth $53,715,000 after buying an additional 171,932 shares during the period. 93.85% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

MLTX has been the subject of a number of recent research reports. Rothschild & Co Redburn initiated coverage on shares of MoonLake Immunotherapeutics in a research note on Monday, July 28th. They issued a “neutral” rating and a $65.00 price objective for the company. HC Wainwright downgraded shares of MoonLake Immunotherapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, October 2nd. Wolfe Research lowered shares of MoonLake Immunotherapeutics from an “outperform” rating to an “underperform” rating in a report on Tuesday, September 30th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $10.00 price target (down from $67.00) on shares of MoonLake Immunotherapeutics in a report on Monday, September 29th. Finally, Needham & Company LLC dropped their price objective on shares of MoonLake Immunotherapeutics from $66.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, September 30th. Three analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $36.00.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.